Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Rheumatoid Arthritis: Human Evidence
Transcript
- 0:00SPEAKER_00: Welcome to the Cyrone Cell Podcast.
- 0:02SPEAKER_01: Glad to be here for this deep dive.
- 0:04SPEAKER_00: Yeah, it's going to be a good one.
- 0:05SPEAKER_00: Usually when we talk about medical diagnosis, there's this expectation of like mechanical precision.
- 0:11SPEAKER_01: Oh, absolutely.
- 0:12SPEAKER_00: You know, you break a bone, they take an x-ray, and it shows that stark, jagged white line.
- 0:17SPEAKER_00: And the doctor just points at it and says, uh, there's the problem.
- 0:20SPEAKER_01: Aaron Powell Yeah.
- 0:21SPEAKER_01: It's visible.
- 0:21SPEAKER_01: It's quantifiable.
- 0:22SPEAKER_00: Aaron Powell And for anyone who's sick, that visibility is just incredibly comforting.
- 0:26SPEAKER_01: Aaron Powell We prefer our biology to act like engineering, broken or not broken, functioning or, you know, completely failing.
- 0:34SPEAKER_00: Aaron Powell But then you step into the world of complex immune conditions, and suddenly that X-ray machine feels completely inadequate.
- 0:42SPEAKER_01: It really does.
- 0:43SPEAKER_00: We're looking at a diagnostic landscape that is just incredibly murky, where the body's internal logic kind of seems to unravel.
- 0:50SPEAKER_01: And that murkiness is tough on patients.
- 0:52SPEAKER_00: It is.
- 0:52SPEAKER_00: So our mission today in this deep dive is to clear up some of that murkiness by unpacking the actual human evidence behind stem cell therapy.
- 1:01SPEAKER_00: We're pulling our sources directly from clinical insights and research data from Sorona Cell, which is a regenerative medicine clinic based in Kuala Lumpur, Malaysia.
- 1:10SPEAKER_01: Aaron Powell And we're drawing a hard line in the sand today.
- 1:12SPEAKER_01: We are focusing entirely on human data.
- 1:16SPEAKER_00: No animal models today.
- 1:17SPEAKER_01: Nope.
- 1:17SPEAKER_01: We're moving past the theoretical laboratory models, skipping the mice studies entirely, and looking strictly at what is happening in real patients dealing with this condition.
- 1:27SPEAKER_00: Grounding this in reality is essential, especially since the landscape of treating rheumatoid arthritis has changed so much over the last two decades, yet still leaves a frustrating number of patients just searching for more.
- 1:40SPEAKER_01: Yeah, there's a big gap there.
- 1:41SPEAKER_00: Aaron Powell Okay, let's unpack this.
- 1:43SPEAKER_00: Because to truly understand the newer treatments, we first need to define the specific enemy we're dealing with here.
- 1:49SPEAKER_01: We do.
- 1:50SPEAKER_01: We need to define it clearly.
- 1:51SPEAKER_00: Aaron Powell We need to separate rheumatoid arthritis or RA from the everyday joint pain that people tend to lump into the bucket of simply, you know, just getting older.
- 2:00SPEAKER_01: Aaron Powell The distinction is foundational for anyone navigating this space because when most people hear the word arthritis, they're picturing osteoarthritis.
- 2:09SPEAKER_00: The typical wear and tear.
- 2:10SPEAKER_01: Yeah, mechanical wear and tear.
- 2:12SPEAKER_01: It's the cartilage in your knee physically wearing down after decades of running or heavy lifting.
- 2:18SPEAKER_00: But RA is completely different.
- 2:20SPEAKER_01: Aaron Powell Completely.
- 2:21SPEAKER_01: Rheumatoid arthritis operates on a totally different paradigm.
- 2:24SPEAKER_01: It is an autoimmune disorder.
- 2:26SPEAKER_00: Aaron Ross Powell Meaning the body turns on itself.
- 2:28SPEAKER_01: Yeah.
- 2:29SPEAKER_01: Your immune system, which exists to defend you against outside threats like viruses or bacteria, makes a critical targeting error.
- 2:36SPEAKER_00: Trevor Burrus It gets confused.
- 2:37SPEAKER_01: It mistakenly identifies the lining of your own joints, the synovium, as a threat, and launches a highly coordinated, relentless attack against it.
- 2:45SPEAKER_00: Aaron Powell It's essentially an inside job.
- 2:47SPEAKER_00: And the way it manifests physically is a massive clue, right?
- 2:51SPEAKER_00: I mean, unlike mechanical wear, which might just affect the one knee you injured playing tennis back in college.
- 2:56SPEAKER_01: Yeah, the asymmetrical wear.
- 2:57SPEAKER_00: Yeah, RA attacks symmetrically.
- 2:59SPEAKER_00: So if your left wrist is swelling and burning, your right wrist is likely doing the exact same thing at the same time.
- 3:04SPEAKER_01: Aaron Powell It's a systemic broadcast.
- 3:06SPEAKER_01: It's happening everywhere.
- 3:07SPEAKER_00: And the stiffness is another big differentiator.
- 3:10SPEAKER_01: Oh, absolutely.
- 3:11SPEAKER_01: It presents with severe morning stiffness, which is a key diagnostic indicator for us.
- 3:15SPEAKER_00: And we aren't talking about needing five minutes to stretch your back out when you get out of bed.
- 3:19SPEAKER_01: No, no.
- 3:20SPEAKER_01: RA stiffness often paralyzes joints for well over an hour.
- 3:24SPEAKER_01: It leaves patients struggling to just grip a toothbrush or even make a cup of coffee in the morning.
- 3:29SPEAKER_01: That sounds exhausting.
- 3:31SPEAKER_01: And because it's a systemic immune issue, the inflammation doesn't just stay in the joints.
- 3:35SPEAKER_01: It can travel.
- 3:36SPEAKER_00: Wait, it goes beyond the joints.
- 3:38SPEAKER_01: Yeah, it can affect the lungs, the heart, or the eyes in some patients.
- 3:42SPEAKER_00: Aaron Powell I always think of the mechanical joint wear, like a car's brake pads wearing down over 100,000 miles.
- 3:48SPEAKER_00: It's just inevitable friction.
- 3:49SPEAKER_01: Trevor Burrus, that's a good way to look at it.
- 3:50SPEAKER_00: Trevor Burrus, but RA is more like the car's own internal security alarm system just glitching out, locking all the doors, and deciding to attack the upholstery and the dashboard from the inside out with acid.
- 4:02SPEAKER_01: Aaron Powell The internal destruction is relentless.
- 4:05SPEAKER_01: RA is a chronic progressive condition.
- 4:07SPEAKER_00: Aaron Powell It doesn't just happen overnight.
- 4:09SPEAKER_01: No, it develops and worsens over years.
- 4:12SPEAKER_01: Which is precisely why getting an early diagnosis from a rheumatologist is critical.
- 4:16SPEAKER_00: Aaron Powell Because you can't reverse the damage once it's done.
- 4:19SPEAKER_01: Yeah.
- 4:19SPEAKER_01: The immune system's attack on the joints doesn't just cause pain.
- 4:23SPEAKER_01: It destroys cartilage and erodes bone.
- 4:26SPEAKER_01: And that physical joint damage cannot be undone once it occurs.
- 4:30SPEAKER_01: So the immediate next step for any patient is intervening early with standard medical treatments to halt that progression.
- 4:36SPEAKER_00: Aaron Powell We can actually catch it much earlier now with blood tests.
- 4:40SPEAKER_01: We can.
- 4:41SPEAKER_01: We can detect specific markers linked to the disease.
- 4:44SPEAKER_00: Like rheumatoid factor or anti-CCP antibodies, sometimes even before the physical symptoms become totally debilitating.
- 4:52SPEAKER_01: And because the damage is irreversible, doctors don't just wait around to see how things develop.
- 4:56SPEAKER_01: They go on the offensive immediately.
- 4:58SPEAKER_00: So what does that offensive look like?
- 5:00SPEAKER_01: The standard playbook for a newly diagnosed patient usually starts with disease-modifying anti-humatic drugs.
- 5:06SPEAKER_00: DMARDs.
- 5:07SPEAKER_01: Yeah, DMARDs is.
- 5:08SPEAKER_01: Methotrexate is a classic example that most people have heard of.
- 5:11SPEAKER_00: And those are the first line of defense.
- 5:13SPEAKER_01: They are the first line choice because their goal is to actively slow the disease progression itself rather than just masking the pain.
- 5:20SPEAKER_00: Mm-hmm.
- 5:21SPEAKER_00: Meanwhile, to handle the day-to-day misery and the acute flare-ups, doctors will deploy NSID's non-steroidal anti-inflammatory drugs, and steroidal anti-inflammatories.
- 5:31SPEAKER_01: But those are purely for symptom relief.
- 5:33SPEAKER_00: Yeah, and relying on steroids long term introduces a whole new set of severe risks.
- 5:38SPEAKER_01: Oh massive risks.
- 5:39SPEAKER_00: Like bone density loss, severe weight gain, and generalized immune suppression.
- 5:44SPEAKER_00: You're sort of trading one problem for another.
- 5:46SPEAKER_01: Which is why the medical field developed biologics.
- 5:49SPEAKER_01: Biologics were a massive revolutionary leap forward in RA care.
- 5:54SPEAKER_00: How are they different from the older drugs?
- 5:56SPEAKER_01: Well, unlike older drugs that broadly dampen the entire immune system, biologics are engineered to target specific individual pathways.
- 6:04SPEAKER_00: Like a sniper approach.
- 6:05SPEAKER_01: Yeah.
- 6:05SPEAKER_01: For example, some biologics specifically target and block a single inflammatory protein called tumor necrosis factor or anti-TNF.
- 6:14SPEAKER_00: Okay, so by blocking that one specific protein, you can shut down a major highway of inflammation.
- 6:20SPEAKER_01: You shut down that one specific route, yeah.
- 6:23SPEAKER_00: But here's the problem.
- 6:24SPEAKER_00: And this is the wall so many of you listening might have hit yourselves.
- 6:27SPEAKER_00: These treatments just don't work equally for everyone.
- 6:30SPEAKER_01: They definitely do not.
- 6:31SPEAKER_00: Side effects accumulate when you take these heavy medications continuously for years.
- 6:36SPEAKER_01: And then there's a phenomenon where a patient is doing incredibly well on a biologic for two years.
- 6:42SPEAKER_00: Getting their life back.
- 6:43SPEAKER_01: And then suddenly it just stops working.
- 6:46SPEAKER_01: Their disease activity remains high despite being on the maximum allowable standard therapy.
- 6:51SPEAKER_00: Aaron Powell Let me push back on the underlying biology here for a second.
- 6:56SPEAKER_00: Because if biologics are successfully targeting the immune system and they're specifically engineered to block that one inflammatory pathway, why do they just fail out of nowhere for some patients?
- 7:08SPEAKER_01: Aaron Powell What's fascinating here is the sheer adaptability and redundancy of the human immune system.
- 7:13SPEAKER_00: It adapts to the drug.
- 7:14SPEAKER_01: It does.
- 7:15SPEAKER_01: It isn't a single light switch.
- 7:16SPEAKER_01: It's a highly complex interconnected network.
- 7:19SPEAKER_01: So when a biologic blocks one specific pathway, let's say that anti-TNF highway, the immune system will sometimes find a workaround.
- 7:28SPEAKER_00: It builds a detour.
- 7:30SPEAKER_01: Exactly that.
- 7:30SPEAKER_01: It essentially builds a detour.
- 7:32SPEAKER_01: It activates a completely different inflammatory cytokine channel to keep the attack going.
- 7:36SPEAKER_00: Aaron Powell Man, so it's like a losing game of whack-a-mole.
- 7:40SPEAKER_01: It can feel that way, yes.
- 7:41SPEAKER_00: You block one inflammatory chemical, and the immune system just ramps up production of a different one to compensate.
- 7:46SPEAKER_01: Furthermore, the body can sometimes recognize the biologic drug itself, which is often a large, complex protein as a foreign substance.
- 7:54SPEAKER_00: Aaron Powell So the body attacks the medicine.
- 7:57SPEAKER_01: Yeah.
- 7:57SPEAKER_01: The patient's immune system develops anti-drug antibodies against the medication.
- 8:02SPEAKER_01: It actively neutralizes the biologic before it can even do its job.
- 8:06SPEAKER_00: Aaron Powell That is incredibly frustrating.
- 8:08SPEAKER_01: It is.
- 8:08SPEAKER_01: That fundamental limitation, blocking just one specific pathway and hoping the body doesn't adapt, leaves a significant portion of patients needing to look beyond standard care.
- 8:18SPEAKER_00: And that frustration, that feeling of hitting a wall where the standard defense is no longer holding the line, is exactly what drives patients to explore alternatives.
- 8:28SPEAKER_01: Naturally, they look for other options.
- 8:29SPEAKER_00: So if blocking a single pathway is failing, the logical next step is trying to reset the broader environment.
- 8:36SPEAKER_01: Which brings us to the stem cell approach.
- 8:38SPEAKER_00: Yeah, and specifically the work being done at clinics like Cyrona Cell.
- 8:42SPEAKER_01: When we talk about stem cells for RA, we need to be highly specific because the terminology gets thrown around a lot in the media.
- 8:48SPEAKER_00: It does, it gets very confusing.
- 8:49SPEAKER_01: We are discussing mesenchymal stem cells.
- 8:52SPEAKER_01: Cyrona cell focuses on a specific sourcing method.
- 8:56SPEAKER_01: Umbilical cord-derived cells, formerly known as Wharton's jelly mesenchymal stem cells, or WJMSCs.
- 9:04SPEAKER_00: Let's break down the how here because this is where the science takes a turn.
- 9:08SPEAKER_00: We just established that biologics act as a highly targeted blockade for one single immune pathway.
- 9:14SPEAKER_01: Yes.
- 9:14SPEAKER_00: But these Wharton's jelly mesenchymal stem cells operate on a completely different level through something called paracrine signaling.
- 9:20SPEAKER_01: They do.
- 9:21SPEAKER_01: They don't just block a pathway, they appear to work broadly across the entire immune system.
- 9:26SPEAKER_00: By releasing a complex cocktail of signals.
- 9:29SPEAKER_01: The mechanism is immunomodulation, not simply immunosuppression.
- 9:33SPEAKER_00: Okay.
- 9:33SPEAKER_00: What does that look like in the body?
- 9:35SPEAKER_01: These cells act almost like tiny chemical factories.
- 9:39SPEAKER_01: When introduced into an inflamed environment, they secrete exosomes and cytokines that actively communicate with the patient's existing immune cells.
- 9:48SPEAKER_00: They're sending messages.
- 9:49SPEAKER_01: Yeah, they send out signals that calm the aggressive immune response, driving the joint damage.
- 9:54SPEAKER_00: Aaron Powell And they don't just stop there, do they?
- 9:56SPEAKER_01: Aaron Powell No.
- 9:56SPEAKER_01: On top of that, they're being actively studied for their ability to support tissue regeneration in the damaged areas around the joint.
- 10:03SPEAKER_00: Aaron Powell I picture it kind of like a Wi-Fi router.
- 10:06SPEAKER_01: A Wi-Fi router.
- 10:07SPEAKER_00: Yeah, like the stem cells are broadcasting a new signal to all the devices, the immune cells in the area, telling them to download a software update that turns off the attack mode.
- 10:15SPEAKER_01: Aaron Powell I like that.
- 10:17SPEAKER_01: Or to go back to our earlier analogies, taking a biologic is like having a bouncer kick one specific troublemaker out of a loud, chaotic nightclub.
- 10:25SPEAKER_00: Mm-hmm.
- 10:25SPEAKER_00: It helps, but the club is still loud.
- 10:28SPEAKER_01: Yeah.
- 10:28SPEAKER_01: And another troublemaker might take his place.
- 10:31SPEAKER_01: Mesenchymal stem cells act more like turning on the house lights, turning off the heavy metal music, and changing the entire environment to calm the whole room down simultaneously.
- 10:40SPEAKER_00: That makes total sense.
- 10:42SPEAKER_00: They essentially re-educate the surrounding environment, reducing the inflammatory signals and promoting a more balanced immune state.
- 10:50SPEAKER_01: We must establish some crucial caveats here, though.
- 10:53SPEAKER_00: Yes, very important.
- 10:54SPEAKER_01: We have to be absolutely clear on the clinical reality.
- 10:57SPEAKER_01: This therapy is not a permanent cure for rheumatoid arthritis.
- 11:01SPEAKER_00: Definitely not a cure.
- 11:02SPEAKER_01: It is not a first-line treatment for a newly diagnosed patient, and it does not automatically replace DMARDs or biologics.
- 11:09SPEAKER_00: It's an option for when standard care fails or falls short.
- 11:13SPEAKER_01: Yes.
- 11:13SPEAKER_00: It's basically another tool in the toolkit when the conventional tools aren't cutting it.
- 11:17SPEAKER_01: And researchers are still working out the optimal standardized protocol.
- 11:21SPEAKER_00: They're still figuring out the fine details.
- 11:23SPEAKER_01: They're actively studying the exact cell counts required, which specific cell sources produce the most reliable immunomodulatory results, and crucially, how long this broad calming effect lasts.
- 11:36SPEAKER_00: Before a patient might need a repeat treatment to maintain that balance.
- 11:39SPEAKER_01: Yeah, exactly.
- 11:40SPEAKER_01: I mean, yeah, that is the goal of the current research.
- 11:43SPEAKER_00: Here's where it gets really interesting, because we promised human evidence today.
- 11:47SPEAKER_00: We're not just talking about theories or what these cells do in a petri dish.
- 11:51SPEAKER_01: No, we're looking at real clinical data.
- 11:54SPEAKER_00: Aaron Powell Let's look at the actual clinical trials involving real patients.
- 11:57SPEAKER_01: The human data is compelling and provides a much clearer picture of the potential here.
- 12:02SPEAKER_01: Let's examine a notable three-year cohort study involving 64 rheumatoid arthritis patients.
- 12:08SPEAKER_00: 64 patients, okay.
- 12:10SPEAKER_01: These individuals combine umbilical cord-derived stem cells with their standard DMARD therapy.
- 12:16SPEAKER_00: So they didn't stop their normal meds.
- 12:17SPEAKER_01: No, they combined them.
- 12:18SPEAKER_01: And the researchers tracked their disease activity scores meticulously over 36 months.
- 12:24SPEAKER_00: And the results showed that their disease activity scores dropped significantly at the one-year mark.
- 12:28SPEAKER_01: Which is great.
- 12:29SPEAKER_00: But the most important part, the part that really matters for chronic disease, is that those scores stayed low at the three-year mark.
- 12:35SPEAKER_01: Sustained relief.
- 12:36SPEAKER_00: Yeah, their health assessment scores, which measure how well they actually function in daily life.
- 12:42SPEAKER_00: You know, can they dress themselves?
- 12:43SPEAKER_00: Can they walk upstairs?
- 12:45SPEAKER_00: Also showed marked improvement.
- 12:46SPEAKER_01: Meanwhile, the placebo group in that same study saw zero meaningful change.
- 12:52SPEAKER_00: Wow.
- 12:53SPEAKER_00: Uh I mean that is a stark contrast.
- 12:56SPEAKER_01: It is.
- 12:56SPEAKER_01: And alongside that long-term cohort study, there's a separate phase IS safety trial that looked closely at the biological mechanisms in nine RA patients.
- 13:06SPEAKER_00: Nine patients who received a single stem cell infusion.
- 13:09SPEAKER_01: Yeah, and they were monitored intensely for four weeks.
- 13:12SPEAKER_00: Four weeks of intense monitoring.
- 13:14SPEAKER_01: The primary goal was safety, and the findings showed no major safety concerns.
- 13:18SPEAKER_00: Were there any side effects at all?
- 13:20SPEAKER_01: Most of the side effects reported were mild and were related to the physical process of the intravenous infusion itself.
- 13:26SPEAKER_00: Like a slight fever or chills from the IV.
- 13:28SPEAKER_01: Yeah, rather than a negative biological reaction to the stem cells.
- 13:31SPEAKER_00: Aaron Powell But they didn't just track safety and tell them to go home.
- 13:34SPEAKER_00: Um, they tracked the specific biomarkers in their blood.
- 13:38SPEAKER_01: The biological data is where things get really fascinating.
- 13:41SPEAKER_00: The markers for systemic inflammation visibly dropped.
- 13:44SPEAKER_00: But simultaneously, the markers linked to regulatory immune cells, specifically regulatory T cells, which are the cells that actually keep the rest of the immune system in check, increased.
- 13:56SPEAKER_01: So you have a measurable reduction in the attack signals and a boost in the body's own peacekeeper signals.
- 14:01SPEAKER_00: But let me ask the skeptical question that's probably on your mind listening to this.
- 14:04SPEAKER_01: Go ahead.
- 14:05SPEAKER_00: Nine patients in one safety trial and 64 in another.
- 14:09SPEAKER_00: In the grand scheme of medical research, is that really enough data to give us absolute confidence in this treatment?
- 14:15SPEAKER_01: If we connect this to the bigger picture, we have to view this through the lens of emerging cellular medicine.
- 14:21SPEAKER_00: Okay, how so?
- 14:22SPEAKER_01: Well, those are relatively small numbers, and larger double-blind, placebo-controlled studies at massive scale are absolutely needed to confirm these patterns across broader demographics.
- 14:33SPEAKER_00: So we do need more data.
- 14:34SPEAKER_01: Yes.
- 14:35SPEAKER_01: However, the fact that the larger cohort study tracked those 64 patients for three full years offers a massive boost in confidence regarding durability.
- 14:45SPEAKER_00: Because a short-term trial only tells you what happens in a temporary vacuum.
- 14:49SPEAKER_01: Yeah.
- 14:50SPEAKER_01: Tracking patients for years proves that the cells are having a sustained, durable impact on the immune system's behavior.
- 14:56SPEAKER_00: Both studies point to meaningful safety and measurable sustained improvement.
- 15:01SPEAKER_01: Which forms a very solid foundation for patients who are just out of standard options.
- 15:05SPEAKER_00: That brings up a massive logistical and practical point for you, the listener, if you're navigating this real-world application.
- 15:11SPEAKER_00: Yeah, if you see this data and decide to explore this route, how do you actually know if it's working for your specific body?
- 15:18SPEAKER_01: That is the big question.
- 15:19SPEAKER_00: Because if you travel to Sorona cell in Kuala Lumpur for this therapy, you're making a significant life commitment.
- 15:26SPEAKER_01: It's a huge undertaking.
- 15:27SPEAKER_00: We need to transition into how doctors measure success in the real world beyond a patient simply walking into the clinic and saying, uh, I feel a bit better today.
- 15:36SPEAKER_01: Subjective feeling is incredibly important to the patient's quality of life, but it isn't a reliable medical metric.
- 15:43SPEAKER_00: Aaron Powell You can't chart a feeling.
- 15:45SPEAKER_01: No.
- 15:45SPEAKER_01: Doctors use a standardized tool called the disease activity score, often the days 28.
- 15:51SPEAKER_00: DASE 28.
- 15:52SPEAKER_01: This is a comprehensive objective metric that combines several hard data points.
- 15:57SPEAKER_00: Like what?
- 15:57SPEAKER_01: Well, they physically count the exact number of swollen and tender joints across 28 specific sites on the body.
- 16:04SPEAKER_00: So they're physically checking?
- 16:06SPEAKER_01: Yes.
- 16:06SPEAKER_01: They incorporate blood markers like CRPC reactive protein and ESR, which measure the sheer volume of systemic inflammation circulating in the blood.
- 16:15SPEAKER_00: And they also use patient health assessment questionnaires and periodic imaging, like ultrasounds or MRIs, to check for any hidden new physical joint damage.
- 16:24SPEAKER_01: All of that data paints a complete picture.
- 16:26SPEAKER_00: And this is where the context of Cyrus being located in Kuala Lumpur becomes deeply relevant to the process.
- 16:31SPEAKER_01: Because the distance.
- 16:32SPEAKER_00: Yeah, they serve a very large international patient base.
- 16:35SPEAKER_00: Traveling across borders for medical care requires serious, meticulous coordination.
- 16:40SPEAKER_01: You don't just book a flight and show up at the clinic.
- 16:43SPEAKER_00: It's a complex medical journey.
- 16:44SPEAKER_01: The coordination between the regenerative clinic in Malaysia and the patient's home doctor is vital for long-term success.
- 16:51SPEAKER_00: They have to talk to each other.
- 16:53SPEAKER_01: Patients must share their full, comprehensive medical records between providers.
- 16:58SPEAKER_01: This ensures that the local rheumatologist back home knows exactly what treatment was received abroad.
- 17:04SPEAKER_00: Down to the exact cell type and count used.
- 17:07SPEAKER_01: Yes, and what the immediate post-treatment blood work looked like.
- 17:11SPEAKER_01: It also prevents the patient from having to undergo duplicated, expensive, and exhausting tests when they return home.
- 17:18SPEAKER_00: Nobody wants to do the same blood panel twice in one week.
- 17:21SPEAKER_01: No, it's exhausting.
- 17:22SPEAKER_00: Before you even pack a bag, a rigorous consultation has to happen.
- 17:26SPEAKER_01: A very detailed consultation.
- 17:28SPEAKER_00: That consultation must review the confirmed diagnosis, the current disease activity, and the prior treatments.
- 17:34SPEAKER_01: The clinical team needs to ask: have you actually tried DMARDs yet?
- 17:38SPEAKER_01: Have you exhausted the standard evidence-based options?
- 17:41SPEAKER_00: They have to set realistic expectations for the next steps.
- 17:44SPEAKER_01: Which highlights why that objective tracking we discussed is absolutely non-negotiable.
- 17:48SPEAKER_00: Consistent tracking catches problems or failures early.
- 17:52SPEAKER_01: If the stem cell therapy isn't yielding the desired immune calming effect, the blood work and the joint counts will reveal that truth far sooner than waiting for a catastrophic flare-up.
- 18:03SPEAKER_00: Before it puts the patient in the hospital.
- 18:04SPEAKER_01: Yeah, the data completely removes the guesswork.
- 18:07SPEAKER_00: There's a severe psychological trap when you live with chronic pain for years.
- 18:12SPEAKER_01: It takes a toll on the mind.
- 18:14SPEAKER_00: You get so desperate for relief that you become highly vulnerable to the placebo effect.
- 18:19SPEAKER_01: You want it to work so badly.
- 18:21SPEAKER_00: You might have a couple of good days where the weather is nice, you're less stressed, and you convince yourself a treatment worked miracles.
- 18:28SPEAKER_01: Or conversely, you have one terrible day, a flare-up, and you spiral, thinking the treatment failed entirely.
- 18:33SPEAKER_00: Tracking the actual CRP levels in your blood and physically counting the inflamed joints protects you from that psychological trap.
- 18:41SPEAKER_01: The data tells the truth, regardless of how you slept the night before.
- 18:44SPEAKER_00: That objective data is the only reliable compass.
- 18:48SPEAKER_00: RA is a relentless adversary.
- 18:51SPEAKER_00: It's an autoimmune condition that requires lifelong vigilant management.
- 18:56SPEAKER_01: The standard treatments, the DRNs, the biologics, they remain the necessary evidence-based starting point for every single patient entering this journey.
- 19:05SPEAKER_00: But what the human data is showing us, particularly with these umbilical cord-derived Wharton's jelly mesenchymal stem cells, is that there is a broader immune-calming option available.
- 19:15SPEAKER_01: There is hope for those who are struggling.
- 19:17SPEAKER_00: For those of you who have played by all the rules, taken the standard medications, endured the side effects, and still aren't finding relief, there is another scientific avenue to explore that goes beyond just blocking a single pathway.
- 19:29SPEAKER_01: We must maintain a grounded perspective on what this means, though.
- 19:32SPEAKER_01: Always.
- 19:33SPEAKER_01: The goal of incorporating stem cell therapy into a protocol is managing the disease activity over the long haul.
- 19:39SPEAKER_00: It's about protecting the cartilage and bone from further destruction and improving the patient's daily mechanical function.
- 19:45SPEAKER_01: It is not about curing the underlying autoimmune condition.
- 19:48SPEAKER_00: The immune system is still fundamentally prone to error, and ongoing monitoring will always be a part of the patient's life.
- 19:55SPEAKER_01: Yes.
- 19:55SPEAKER_00: It completely changes the paradigm of how we look at the disease, though.
- 19:59SPEAKER_01: It really does.
- 20:00SPEAKER_00: We've spent decades trying to suppress the immune system to treat autoimmune diseases.
- 20:05SPEAKER_00: We build massive expensive drugs to block pathways, to shut down responses.
- 20:11SPEAKER_01: Essentially putting the entire immune system in a chemical straitjacket.
- 20:14SPEAKER_00: But looking at how those regulatory immune markers, those peacekeeper T cells, actually increased in the safety trials.
- 20:21SPEAKER_00: What if the future of medicine isn't about fighting the immune system, but rather reteaching it how to find its own balance?
- 20:29SPEAKER_01: That is the ultimate frontier of regenerative medicine.
- 20:32SPEAKER_01: We are shifting from mere suppression to active modulation.
- 20:36SPEAKER_00: That shift is huge.
- 20:37SPEAKER_01: We're observing these cells, providing a new set of instructions to a confused, overactive immune system, asking it to stand down rather than simply forcing it into submission.
- 20:47SPEAKER_00: So what does this all mean?
- 20:49SPEAKER_00: It means there's always more to learn.
- 20:51SPEAKER_00: And the human body is far more adaptable than we give it credit for.
- 20:55SPEAKER_00: Thank you for joining us on this deep dive into the data, the biology, and the future of treating complex joint conditions.
- 21:02SPEAKER_00: Keep asking questions, keep looking at the hard evidence, and we will see you on the next one.